Previous 10 | Next 10 |
home / stock / sbhmy / sbhmy news
Summary The recent unprecedented national security incident created by suspected Chinese spy balloons and other aerial objects ratchet up geopolitical tensions and put F-star's acquisition by Sino Biopharmaceutical at significant risk. F-star's controversial acquisition by Sino Biopharm...
Summary HutchMed out-licensed global rights (ex-China) for a colorectal cancer therapy, fruquintinib, to Takeda Pharmaceutical in a deal worth up to $1.13 billion, including $400 million upfront. Guangzhou Akeso was approved to market penpulimab, an anti PD-1 mAb, as a first-line treatm...
Summary FSTX seems undervalued, even at the $7.12 takeover bid. The CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns. If the deal closes, the stock should rise 30%; if it fails, FSTX still has very valuable assets. The only r...
Summary The odds are now in favor of a successful completion of the Sino Biopharmaceutical/F-star merger as the UK government has approved the deal. CFIUS is the final hurdle before the deal can close. While CFIUS approval is not a slam dunk, the latest developments point towa...
Summary Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharm, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from France’s Inventiva in a $307 million deal. Immuno Cure, a Hong Kong biotech focused on DNA vaccines and immunotherapies, acq...
Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion HONG KONG, Aug 23, 2022 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177...
invoX Pharma, a Sino Biopharm subsidiary, will pay $161 million to acquire F-Star, a Cambridge, UK clinical-stage company developing bispecific drugs for immunotherapies. Xuanzhu Biopharm of Shandong out-licensed China rights for two anti-infectives to Shanghai SPH New Asia Pharma in ...
China's Sino Biopharmaceutical's ( OTCPK:SBHMY ) ( OTCPK:SBMFF ) unit invoX Pharma is acquiring F-star Therapeutics ( NASDAQ: FSTX ) in a $161M all-cash deal. U.K.-based invoX will begin a tender offer within 10 business days to acquire all the issued and ...
Vivo Capital, a US-China healthcare investor, held its first closing of a yuan-denominated private equity fund at $600 million, with a target of bringing the fund to $1.5 billion. SciNeuro Pharma, a Shanghai CNS company, acquired global rights to Lp-PLA2 inhibitors for neurodegenerati...
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in a $125 million agreement. Oncotelic Therapeutics, a South San Francisco company, formed a Hong Kong JV with Dragon Overseas Capital to develop TGF-β therapeutics. ...
News, Short Squeeze, Breakout and More Instantly...
Sino Biopharmaceutical Ltd ADR Company Name:
SBHMY Stock Symbol:
OTCMKTS Market:
Sino Biopharm (1177.HK) Announces 2023 Annual Results HONG KONG, Mar 29, 2024 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the...
Sino Biopharmaceutical (1177.HK) Announces 2023 Interim Results HONG KONG, Aug 25, 2023 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical ...
Sino Biopharm (1177.HK) Announces 2022 Annual Results HONG KONG, Mar 31, 2023 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the...